French software developer Median Technologies has been selected as one of the first 50 companies to participate in the new ETIncelles Program of the French government.
French President Emmanuel Macron launched the national ETIncelles Program on November 21st at Elysée Palace. This is a strategic initiative designed to bolster the growth and development of small- and medium-sized enterprises (SMEs) into midsized businesses. One of the program's objectives is to produce 500 companies with high growth potential into midsize businesses within Macron's second term, ending 2027.
The new program helps SMEs identify obstacles to their growth, especially administrative aspects, with the aim of better overcoming them and acting as a catalyst for the development and conversion into an intermediate-sized enterprise.
In other Median news, the company has rebranded its iBiopsy AI/machine learning tech-based suite of software as a medical devices business unit named Eyonis.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
